352 (PB132) - Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study
| Autor: | Saggu, G., Stroopinsky, D., Dudek, A.Z., Olszanski, A.J., Juric, D., Dowlati, A., Vaishampayan, U., Assad, H., Rodón, J., Gibbs, J., Green, J., Du, Z., Rudicell, R., Kannan, K., Gharavi, R., Gomez-Pinillos, A., Fram, R.J., Berger, A., Sachsenmeier, K., Kasar, S. |
|---|---|
| Zdroj: | In European Journal of Cancer October 2022 174 Supplement 1:S125-S126 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect